SG11201806348PA - Steroid derivative fxr agonist - Google Patents

Steroid derivative fxr agonist

Info

Publication number
SG11201806348PA
SG11201806348PA SG11201806348PA SG11201806348PA SG11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA
Authority
SG
Singapore
Prior art keywords
fxr agonist
steroid derivative
derivative fxr
relates
steroid
Prior art date
Application number
SG11201806348PA
Inventor
Haiying He
Hualing Xiao
Peng Li
Chunyan Du
Zhi Luo
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11201806348PA publication Critical patent/SG11201806348PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a compound represented by formula (I), a tautomer thereof a acceptable thereof, relates applications thereof in the preparation of drugs for treating FXR related diseases.
SG11201806348PA 2016-01-28 2017-01-25 Steroid derivative fxr agonist SG11201806348PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610061293 2016-01-28
CN201610331759 2016-05-18
PCT/CN2017/072567 WO2017129125A1 (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Publications (1)

Publication Number Publication Date
SG11201806348PA true SG11201806348PA (en) 2018-08-30

Family

ID=59397430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913768TA SG10201913768TA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist
SG11201806348PA SG11201806348PA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913768TA SG10201913768TA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Country Status (15)

Country Link
US (2) US10875888B2 (en)
EP (1) EP3409684B1 (en)
JP (1) JP6924765B2 (en)
KR (1) KR20180100703A (en)
CN (1) CN109071593B (en)
AU (2) AU2017213032B2 (en)
CA (1) CA3012396C (en)
CL (1) CL2018002009A1 (en)
IL (1) IL260795B (en)
MX (1) MX2018009175A (en)
MY (1) MY196292A (en)
PH (1) PH12018550120A1 (en)
SG (2) SG10201913768TA (en)
WO (1) WO2017129125A1 (en)
ZA (1) ZA201805231B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015343025A1 (en) 2014-11-06 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs an FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
JP2017535570A (en) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Bile acid analogs as FXR / TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2017130466A (en) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. BILIC ACID ANALOGUES AS FXR / TGR5 AGONISTS AND WAYS OF THEIR APPLICATION
EP3277286B1 (en) 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
KR20180100703A (en) * 2016-01-28 2018-09-11 치아타이 티안큉 파마수티컬 그룹 주식회사 Steroid derivatives FXR function bodies
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2019006165A (en) 2016-11-29 2019-10-14 Enanta Pharm Inc Process for preparation of sulfonylurea bile acid derivatives.
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN109134572A (en) * 2017-06-19 2019-01-04 中国科学院上海药物研究所 Chlolic acid derivatives and its preparation method and application
WO2019020067A1 (en) * 2017-07-26 2019-01-31 正大天晴药业集团股份有限公司 Method for preparing steroid derivative fxr agonist
CN110869382B (en) * 2017-07-26 2021-06-25 正大天晴药业集团股份有限公司 Steroid derivative FXR agonist crystal or amorphous substance, preparation method and application thereof
CN107383139A (en) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 The method that a kind of β cholanic acid new derivatives of 7 oxo of 3 α hydroxyls 5 prepare shellfish cholic acid difficult to understand
US11111265B2 (en) * 2017-11-02 2021-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
CN107722000A (en) * 2017-11-03 2018-02-23 中国药科大学 The preparation of the berberinc derivate of 9-substitution and its medical usage
CN107987116B (en) * 2018-01-17 2021-01-05 中国药科大学 Chenodeoxycholic acid derivatives, preparation method and medical application thereof
CN116178473A (en) * 2018-12-10 2023-05-30 江西青峰药业有限公司 Preparation method of obeticholic acid
JP2022540699A (en) 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ How to reduce the adverse effects of interferon
CN110878113B (en) * 2019-11-07 2021-02-02 成都贝诺科成生物科技有限公司 Cholic acid derivative with antibacterial activity and medicinal composition thereof
JP2023510274A (en) 2020-01-15 2023-03-13 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Use of FXR agonists to treat infection by hepatitis D virus
MX2023008365A (en) 2021-01-14 2023-10-04 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection.
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN113861258A (en) * 2021-09-05 2021-12-31 中国海洋大学 Method for synthesizing sargasterol
WO2023048528A1 (en) * 2021-09-24 2023-03-30 (주)샤페론 Pharmaceutical composition comprising inflammasome inhibitor as active ingredient for prevention, alleviation, or treatment of atopic dermatitis
KR20230043773A (en) * 2021-09-24 2023-03-31 (주)샤페론 Pharmaceutical composition for preventing, improving or treating non-alcoholic steatohepatitis, liver fibrosis comprising inflammasome inhibitor compound as an active ingredient
WO2023233346A1 (en) * 2022-06-01 2023-12-07 Precision Bio-Therapeutics S.R.L. Cholesterol derivatives and their uses
CN116497082B (en) * 2023-06-27 2023-09-29 华南理工大学 Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
WO2002072598A1 (en) * 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US9084826B2 (en) * 2012-05-01 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists; compositions and method of uses
CA2957332A1 (en) * 2014-08-20 2016-02-25 F. Hoffmann-La Roche Ag In vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
JP2017535570A (en) * 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Bile acid analogs as FXR / TGR5 agonists and methods of use thereof
US10208081B2 (en) * 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3277286B1 (en) * 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016173493A1 (en) * 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
US20180148470A1 (en) 2015-04-28 2018-05-31 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
KR20180100703A (en) * 2016-01-28 2018-09-11 치아타이 티안큉 파마수티컬 그룹 주식회사 Steroid derivatives FXR function bodies
WO2017147137A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10407176B2 (en) * 2016-03-31 2019-09-10 B/E Aerospace, Inc. Pretensioner for retractable shoulder belt and seat belt

Also Published As

Publication number Publication date
PH12018550120A1 (en) 2019-03-18
CN109071593B (en) 2021-01-15
ZA201805231B (en) 2022-03-30
EP3409684A4 (en) 2019-10-09
MX2018009175A (en) 2018-11-29
AU2017213032A1 (en) 2018-08-30
CL2018002009A1 (en) 2018-11-05
BR112018015474A2 (en) 2018-12-18
AU2017213032B2 (en) 2021-01-07
SG10201913768TA (en) 2020-03-30
EP3409684A1 (en) 2018-12-05
AU2021202018B2 (en) 2022-04-07
EP3409684B1 (en) 2024-01-03
CA3012396C (en) 2024-03-26
CA3012396A1 (en) 2017-08-03
US10875888B2 (en) 2020-12-29
CN109071593A (en) 2018-12-21
US20190382437A1 (en) 2019-12-19
IL260795B (en) 2021-04-29
US20210040140A1 (en) 2021-02-11
JP6924765B2 (en) 2021-08-25
AU2021202018A1 (en) 2021-04-29
WO2017129125A1 (en) 2017-08-03
US11667667B2 (en) 2023-06-06
MY196292A (en) 2023-03-24
KR20180100703A (en) 2018-09-11
JP2019503392A (en) 2019-02-07

Similar Documents

Publication Publication Date Title
SG11201806348PA (en) Steroid derivative fxr agonist
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12019500480A1 (en) Pyridine compound
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
MY197698A (en) Oxysterols and methods of use thereof
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201791304A1 (en) IZOHINOLINA DERIVATIVES FOR HIV TREATMENT
JOP20170101B1 (en) SYNTHESIS of INDAZOLES
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12016502246A1 (en) Carboxamide derivatives
MX2016014946A (en) Carboxamide derivatives.
JOP20200030A1 (en) Pentacyclic compound
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2018016339A (en) Anti-infective heterocyclic compounds and uses thereof.
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
EA038580B9 (en) Steroid derivative fxr agonist
MY190171A (en) Synthesis of indazoles